|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.250 GBX | 0.00% |
|
0.00% | -32.56% |
| Jun. 03 | Valereum invests in Blubird; Hemogenyx raises funds | AN |
| Jun. 03 | Renalytix Forms Prognostic Test Partnership in US | MT |
| Capitalization | 32.65M 28.17M 26.48M 24.01M 44.27M 2.81B 49.96M 309M 120M 1.29B 122M 120M 4.7B | P/E ratio 2023 |
-2.58x | P/E ratio 2024 | -0.45x |
|---|---|---|---|---|---|
| Enterprise value | 36.5M 31.5M 29.61M 26.85M 49.5M 3.14B 55.86M 345M 135M 1.44B 137M 134M 5.26B | EV / Sales 2023 |
35,707,020x | EV / Sales 2024 | 11,059,330x |
| Free-Float |
72.07% | Yield 2023 * |
-
| Yield 2024 | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Renalytix Plc
More recommendations
More press releases
More news
| Current month | -9.38% | ||
| 1 month | -12.12% | ||
| 3 months | -19.44% | ||
| 6 months | -23.68% | ||
| Current year | -32.56% |
| 1 week | 7 |  | 7.45 |
| 1 month | 7 | | 9 |
| Current year | 7 | | 12.99 |
| 1 year | 6.5 | | 19.96 |
| 3 years | 6.5 | | 177 |
| 5 years | 6.5 | | 1,220 |
| 10 years | 6.5 | | 1,220 |
| Manager | Title | Age | Since |
|---|---|---|---|
James McCullough
CEO | Chief Executive Officer | 57 | 2018-03-14 |
Joel Jung
DFI | Director of Finance/CFO | 67 | 2024-05-27 |
Howard Doran
PSD | President | 64 | 2024-04-29 |
| Director | Title | Age | Since |
|---|---|---|---|
Julian Baines
CHM | Chairman | 61 | 2024-11-04 |
James McCullough
BRD | Director/Board Member | 57 | 2018-03-14 |
| Chairman | 72 | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| 0.00% | 0.00% | -62.34% | -95.74% | 32.64M | ||
| +4.09% | +4.14% | -12.90% | -33.08% | 14.9B | ||
| +1.11% | -1.05% | -19.84% | -70.87% | 1.95B | ||
| 0.00% | -6.03% | -19.45% | - | 1.23B | ||
| +1.46% | -2.20% | -39.03% | +167.39% | 1.22B | ||
| -0.21% | -0.07% | -16.93% | -19.38% | 1.2B | ||
| -6.47% | -11.76% | -2.41% | -8.09% | 989M | ||
| +2.55% | -2.09% | +5.24% | -36.57% | 843M | ||
| -0.93% | -1.99% | -1.43% | -49.38% | 779M | ||
| +2.68% | -1.13% | -24.19% | -40.06% | 470M | ||
| Average | +0.43% | -2.27% | -19.33% | -20.64% | 2.36B | |
| Weighted average by Cap. | +2.58% | +1.03% | -14.20% | -24.58% |
| 2023 | 2024 | |
|---|---|---|
| Net sales | 3.4 2.94 2.76 2.5 4.61 292.39 5.21 32.19 12.54 133.95 12.77 12.5 490.37 | 2.29 1.98 1.86 1.68 3.1 196.67 3.5 21.65 8.44 90.1 8.59 8.41 329.84 |
| Net income | -45.61M -39.35M -36.99M -33.54M -61.84M -3.92B -69.79M -431M -168M -1.8B -171M -168M -6.57B | -33.46M -28.87M -27.13M -24.61M -45.37M -2.87B -51.19M -316M -123M -1.32B -126M -123M -4.82B |
| Net Debt | -12.56M -10.84M -10.19M -9.24M -17.04M -1.08B -19.22M -119M -46.31M -495M -47.14M -46.14M -1.81B | 3.86M 3.33M 3.13M 2.84M 5.23M 331M 5.9M 36.46M 14.21M 152M 14.46M 14.16M 556M |
More financial data
* Estimated data
Employees
102
Calendar
2025-06-16
- Q3 2025 Earnings Release (Projected)
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-06-16 | 7.250 p | 0.00% | 20,256 |
| 25-06-13 | 7.250 p | 0.00% | 61,524 |
| 25-06-12 | 7.250 p | 0.00% | 66,884 |
| 25-06-11 | 7.250 p | 0.00% | 8,689 |
| 25-06-10 | 7.250 p | 0.00% | 114,790 |
Delayed Quote London S.E., June 16, 2025 at 11:35 am EDT
More quotes
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- RENX Stock
Select your edition
All financial news and data tailored to specific country editions
